Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
A large analysis of weight-loss drugs like Ozempic and Wegovy has surprised health researchers, who found links to multiple new benefits – and some new side effects.
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback